CD37 antibody

June 19, 2018

Trial of Betalutin-Rituxan Combo as Second-line Follicular Lymphoma Therapy Poised to Launch in Norway

News

A Phase 1b trial evaluating a combination of Betalutin (177Lu-satetraxetan-lilotomab) and Rituxan (rituximab) as a second-line therapy for follicular lymphoma will begin soon in Norway following Nordic Nanovector receiving all necessary approvals. The trial, called Archer-1, ... Read more

April 18, 2018

Humalutin Inhibits Tumor Growth in Non-Hodgkin’s Lymphoma, Preclinical Study Shows

News

Humalutin (177Lu-NNV003), a novel tumor-targeting antibody labeled with radiation, demonstrated promising results in animal models of non-Hodgkin’s lymphoma (NHL), Nordic Nanovector announced. Humalutin is an investigational, humanized version of Betalutin — Nordic’s lead therapy candidate ... Read more